MB
SPRY icon

MPM BioImpact’s ARS Pharmaceuticals SPRY Stock Holding History

MPM BioImpact’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,303,399
Closed -$13.1M – 51
2025
Q3 		$13.1M Hold
1,303,399
– – 2.14% 22
2025
Q2 		$22.7M Sell
1,303,399
-9,705
-0.7% -$140K 3.94% 5
2025
Q1 		$16.5M Buy
+1,313,104
New +$15.8M 2.84% 13

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

MPM BioImpact's SPRY Position: Q4 2025 in Review

MPM BioImpact sold out of ARS Pharmaceuticals (SPRY) in Q4 2025, closing a stake of 1,303,399 shares — an estimated $13.1M sold.

MPM BioImpact first reported a position in SPRY in Q1 2025 and held it in 3 quarters. The position peaked at $22.7M in Q2 2025. 190 funds tracked by Wall St. Rank hold SPRY as of Q4 2025.

  • MPM BioImpact reported no remaining ARS Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • MPM BioImpact sold 1,303,399 ARS Pharmaceuticals shares in Q4 2025, an estimated $13.1M.
  • MPM BioImpact first reported a position in ARS Pharmaceuticals in Q1 2025 and held it in 3 quarters.
  • MPM BioImpact's ARS Pharmaceuticals position peaked at $22.7M in Q2 2025.
  • 190 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q4 2025.

Based on MPM BioImpact's 13F filing for Q4 2025, filed 17 Feb 2026.